Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Trinh Le  Huy; My Hanh Bui; Toi Chu Dinh; Hoang Thi Hong  Xuyen

doi:10.3889/oamjms.2019.368

Authors

Trinh Le Huy Department of Oncology, Hanoi Medical University Hospital, Hanoi, Vietnam
My Hanh Bui Tuberculosis and Lung Disease Department, Hanoi Medical University, Hanoi, Vietnam; Scientific Research & International Cooperation Department, Hanoi Medical University Hospital, Hanoi, Vietnam
Toi Chu Dinh Department of Human and Animal Physiology, Faculty of Biology, Hanoi National University of Education, Hanoi, Vietnam
Hoang Thi Hong Xuyen Center for Development of Curriculum and Human Resource in Health, Hanoi Medical University, Hanoi. Vietnam

DOI:

https://doi.org/10.3889/oamjms.2019.368

Keywords:

Efficacy, Toxicity, Folfoxiri, Metastatic colorectal cancer

Abstract

BACKGROUND: In recent times, scientists have found new treatments for colorectal cancer patients.

AIM: The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV.

METHODS: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients.

RESULTS: The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 Â± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage.

CONCLUSIONS: The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.